Reporte zur Charge EL9202, handwri

Symptomtext

noticed a rash/rash on her back; bumpy/bumpy on her back; itchy/itchy on her back; This is a spontaneous report from a contactable consumer (patient). A 87-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: EL9202 and Expiration date was unknown), via an unspecified route of administration in left arm on 16Feb2021 at 10:00AM (at the age of 87-year-old) as dose 1, single for COVID-19 immunisation. The patient medical history included cholesterol. There was no family medical history. History including any illness at time of vaccination was none. Concomitant medications included Cyanocobalamin (B12), ongoing Rosuvastatin (5mg; take once daily by mouth) taken for Cholesterol, One a Day Vitamin. There was no other vaccines received prior vaccinations (within 4 weeks). History of all previous immunization with the Pfizer vaccine considered as suspect was reported as none. There was no additional vaccines administered on same date of the Pfizer suspect. On 23Feb2021, the patient experienced rash on her back, itchy on her back and bumpy on her back. It was reported that patient received the first dose of the Pfizer COVID vaccine on 16Feb2021. Stated that she noticed a rash a week later that was itchy and bumpy on half of her back and it is still there today. She is scheduled for the second dose of the vaccine this Friday at 10 AM. Consumer stated that she thought before she goes for the second shot, she should consult with someone about the rash on her back mostly. She didn't connect it with the shot at first but now she is concerned about whether she should get the second dose. She would like to know if she should receive the second the dose of the vaccine since she had the rash after the first dose. AEs does not require a visit to physician or ER. There was no relevant test done. There was no investigation assessment. Outcome of the events was reported as not recovered. No follow-up attempts are possible. No further information is expected.